Democritus University of Thrace (DUTH)
Ο ρόλος των μεμβρανικών γλυκοπρωτεϊνών στον καρκίνο των ωοθηκών
Abstract
dc:descriptionIn advanced ovarian cancer disease responses to chemotherapy are very low and are characterized with early relapse. Metastasis in the peritoneal cavity is one of the main caveats and there is no effective treatment to reduce metastasis and consequently limit disease evolution.In this study we report the effect of blocking CA125-mesothelin mediated cell adhesion in a mouse model system permitting in vivo imaging of peritoneal metastasis. We developed a luciferase-based system to monitor peritoneal metastasis progression. One day after IP implantation of luciferase-transfected human ovarian cancer cells (OVCAR5), mice were injected intraperitoneally (IP) with 5 mg/Kgr of anti-CA125 mAb (X52) and/or anti-mesothelin mAb (K1) or anti-mesothelin Bb (P4). Our preclinical study demonstrated that IP injections of acombination of X52 and K1 resulted in reduced tumor micrometastasis as assessed by in vivo imaging. Further analysis of the tumor microenvironment revealed a diminished presence of myeloid-derived suppressor cells (MDSCs).Tumoral mucins, which are heavily glycosylated tumor antigens such as mesothelin are attached to tumor cells by mannose residue-containing glycolipids (GPI anchors). However, the binding of soluble mesothelin via mannose residues to mannose receptor has not been systematically studied. To address this issue, we analyzed the binding of tumor-released mesothelin to ascites-infiltrating macrophages from ovarian cancer patients. We also modeled functional interactions between macrophages and soluble mesothelin using an in vitro system of co-culture of healthy donor macrophages with human ovarian cancer cell lines in transwells. We found that soluble mesothelin binds to human macrophages and that the binding depended on the presence of GPI anchor and mannose receptor. We next challenged the system with antibodies directed against the mannose receptor domain 4 (CDR4-MR). We isolated three novel anti-CDR4-MR human recombinant antibodies (scFv) using a yeast-display library of human scFv. Anti-CDR4-MR scFv #G11 could block mesothelin binding to macrophages and prevent tumor-induced phenotype polarization of CD206low macrophages towards TAMs. Our findings indicate that tumor-released mesothelin is linked to GPI anchor, engages macrophage mannose receptor, and contributes to macrophage polarization towards TAMs. We propose that compounds capable of blocking tumor antigen GPI anchor/CD206 interactions, such as our novel anti-CRD4-MR scFv, could prevent tumor-induced TAM polarization and have therapeutic potential against ovarian cancer, through controlling the polarization of tumor-infiltrating innate immune cells.Studying the tumor microenvironment is critical for designing appropriate therapeutic strategies against ovarian cancer. The cell surface protein B7-H4 (B7x/B7s) is expressed by various cancers and B7-H4+ tumor-associated macrophages (TAMs) or surrogate APCs negatively regulate T cell activation, possibly through interaction with a putative receptor, suggesting that targeting of surface B7-H4 with affinity reagents could mediate clinical effects. We studied B7-H4 cell surface expression in human samples from ovarian cancer ascites and solid tumors, as well as in human ovarian cancer cell lines after mouse passage and/or short term culture. B7-H4 was expressed on tumor-infiltrating macrophages and freshly harvested tumor cells derived from cancer patients and from a mouse xenograft model. However, B7-H4 cell surface expression was downregulated on tumor cells after short term in vitro culture. We next isolated anti-B7-H4 recombinant antibodies (scFvs) by differential screenings of a yeast-display scFv library derived from ovarian cancer patient's human B lymphocytes. Anti-B7-H4 scFvs reversed T-cell inhibition mediated by a B7-H4 recombinant protein, in response to anti-CD3 stimulation. Furthermore, anti-B7-H4 scFv 3#68 restored antigen-specific T cell suppression, mediated by B7-H4+ antigen-loaded APCs or B7-H4+ tumor cells (presentation in cis), and by TAMs (presentation in trans). Our data demonstrate that B7-H4 cell surface expression is inducible in vivo which enables cell surface targeting strategies against B7-H4, and further show that antibody blockade of B7-H4 can restore anti-tumor T cell responses in vitro.Ιn summary, we have elucidated the role of the abundant tumor released glycoproteins such as mesothelin and CA125 in the promotion of ovarian micrometastasis. Furthermore, we studied the consequences of mesothelin binding to its newly identified ligand, the macrophage mannose receptor. We found that blockade of such interactions could protect macrophages from tumor polarizationand preserve their pro-inflammatory phenotype. Moreover, we characterized the expression of B7-H4 in the ovarian cancer microenvironment and the B7-H4-mediated inhibition of tumor antigen-specific T cells. Finally, we identified novel anti-MR and anti-B7-H4 recombinant antibodies and evaluated their application for the development of new immunotherapeutic methods against ovarian cancer.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Dangaj, Denarda
- Ντάνγκαη, Ντενάρντα
Subjects
dc:subject × 22- Καρκίνος ωοθηκών
- Μεμβρανική γλυκοπρωτεΐνη
- Καρκινικοί δείκτες
- Στόχευση μεμβρανικών γλυκοπρωτεϊνών
- Ανοσοποιητικό σύστημα
- Άνασυνδυασμένα αντισώματα
- Προαγωγή ανοσολογικών αποκρίσεων κατά καρκινικών γλυκοπρωτεϊνών
- Μονή αλυσίδα αντισώματος
- Ovarian cancer
- Membrane glycoprotein
- Tumor biomarker
- Targeting of membrane glycoproteins
- Immune system
- Antibodies
- Enhancement of immune responses against tumor glycoproteins
- Single chain fragment variable (scFv)
- Φυσικές Επιστήμες
- Βιολογία
- Ιατρική και Επιστήμες Υγείας
- Natural Sciences
- Biological Sciences
- Medical and Health Sciences
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/28401